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Human rhinoviruses (HRV) are the most common cause of viral respiratory tract
infections. While normally mild and self-limiting in healthy adults, HRV infections are
associated with bronchiolitis in infants, pneumonia in immunocompromised patients,
and exacerbations of asthma and COPD. The human cathelicidin LL-37 is a host
defense peptide (HDP) with broad immunomodulatory and antimicrobial activities that
has direct antiviral effects against HRV. However, LL-37 is known to be susceptible to
the enzymatic activity of peptidyl arginine deiminases (PAD), and exposure of the peptide
to these enzymes results in the conversion of positively charged arginines to neutral
citrullines (citrullination). Here, we demonstrate that citrullination of LL-37 reduced its
direct antiviral activity against HRV. Furthermore, while the anti-rhinovirus activity of LL-37
results in dampened epithelial cell inflammatory responses, citrullination of the peptide,
and a loss in antiviral activity, ameliorates this effect. This study also demonstrates that
HRV infection upregulates PAD2 protein expression, and increases levels of protein
citrullination, including histone H3, in human bronchial epithelial cells. Increased PADI
gene expression and HDP citrullination during infection may represent a novel viral
evasion mechanism, likely applicable to a wide range of pathogens, and should therefore
be considered in the design of therapeutic peptide derivatives.
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INTRODUCTION
Human rhinovirus (HRV) is the most common cause of upper respiratory tract infection and a
causative agent of the common cold (1). HRV infections are associated with bronchiolitis in infants
and children, as well as fatal pneumonia in elderly or immunocompromised individuals (1, 2). HRV
infection can also result in exacerbations of pre-existing respiratory conditions, such as asthma
and chronic obstructive pulmonary disease (COPD) (3, 4). In addition, children who experience
wheezing as a result of HRV infection are at increased risk of subsequently developing asthma (5).
Around 150 different serotypes of HRV have been identified so far and collectively, these represent
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a significant burden of morbidity and mortality as well as
substantial healthcare costs (6). There are currently no effective
therapeutics, or preventative vaccines, licensed for use to treat or
prevent HRV infection.
HRV are non-enveloped, single stranded RNA (ssRNA)
viruses of the Picornaviridae family. All serotypes of HRV use
receptor-mediated endocytosis (via ICAM-1 or LDLR) to infect
upper airway epithelial cells where viral replication occurs (7, 8).
Following HRV infection, cells secrete inflammatory mediators
such as IL-1β, IL-6, and IL-8, which correlate with the severity
of symptoms and neutrophil infiltrates (9, 10). Airway epithelial
cells and infiltrating leukocytes can also respond to viral infection
with the secretion of host defense peptides (HDP), also known as
antimicrobial peptides (11, 12).
One of the best characterized HDP with potent antiviral
activity is the human cathelicidin LL-37. LL-37 is the active
cleaved fragment of the sole human cathelicidin, hCAP-18
(13). This peptide is primarily found in neutrophil specific
granules but can also be produced and secreted by various cell
types including epithelial cells, macrophages and lymphocytes
(14). Altered Cathepsin C-mediated processing of hCAP-18,
or neutropenic deficiency of LL-37 in humans is reflected
by increased susceptibility to infection (15, 16), and mice
lacking the cathelicidin gene exhibit increased susceptibility
to both bacterial and viral infections (17, 18). Conversely,
exogenous delivery of LL-37 in murine models offers increased
protection against, and enhanced resolution of, respiratory viral
infections (18, 19).
LL-37 concentrations are increased at sites of inflammation,
including the lungs, where the peptide can act directly against
a range of respiratory pathogens including influenza virus
(IAV), Mycobacterium tuberculosis, Pseudomonas aeruginosa,
and Respiratory Syncytial Virus (RSV) (19–21). The size,
amphipathicity and cationic charge of LL-37 are all important
determinants of its direct antimicrobial activity (22) and the five
arginine residues in LL-37 critically contribute to the cationic
nature of the peptide. In this regard, the core region of LL-37
[20 residues, (13–32)], which includes three arginine residues, is
required for its antiviral activity against both IAV and RSV and
may also be critical in the antiviral activity of the peptide against
other pathogens (20, 23, 24).
Recent work has shown that posttranslational modifications
can alter the structure and function of a wide range of HDP
(25). Citrullination or deimination is the post-translational
conversion of arginine residues within a protein or peptide to
the non-coded and neutrally charged amino acid citrulline. This
results in the loss of 1 positive charge per arginine converted,
which can substantially alter protein folding, structure, and
function (26). Citrullination is mediated by a family of calcium
binding enzymes, peptidylarginine deiminases, or PADs (EC
3.5.3.15). Five different isoforms of PAD enzymes exist in
humans (PAD1, 2, 3, 4, and 6), with varying substrate specificity
and tissue distribution (26). While structural proteins such as
vimentin, filaggrin, or fibronectin are among the most studied
substrates of PAD enzymatic activity, secreted and nuclear
proteins such as chemokines and histones are also targets of PAD
enzymes (26, 27).
Protein citrullination and PAD activity are important
in a number of physiological processes, such as epidermis
differentiation, apoptosis, gene transcription or Neutrophil
Extracellular Trap (NET) formation (26). However, auto-
antibodies against citrullinated proteins are a hallmark
of rheumatoid arthritis, and abnormally elevated levels of
citrullinated proteins and PAD enzymes are found in a number
of inflammatory pathologies (28). It is known that PAD2
and PAD4, together with total citrullinated protein levels, are
elevated in the lungs under inflammatory conditions such as
tobacco smoking, COPD, or exposure to nanoparticles (29–33).
Importantly, blocking PAD enzymatic activity has been shown to
reduce inflammation in several mouse models of inflammation,
including allergic airway inflammation (34).
PAD2 and PAD4 isoforms have been shown to citrullinate
LL-37 in vitro, profoundly disrupting the direct antibacterial
activity of LL-37 (30) and the well-established capacity of the
peptide to reduce inflammation in response to lipopolysaccharide
(LPS) (35). Furthermore, citrullination results in increased
susceptibility of LL-37 to degradation by bacterial or host cell
proteases (30).
Previous work from our group, and others, has shown that
LL-37 has direct antiviral activity toward HRV viruses (36–38).
Given that citrullination can profoundly affect the functions of
LL-37, and that PAD activity is increased under inflammatory
conditions, we aimed to establish the impact of citrullination
on the antiviral activity of LL-37 against HRV. Furthermore,
we investigated whether infection with HRV results in increased
PADI gene and PAD protein expression and increased protein
citrullination in human bronchial epithelial cells.
We show that citrullination of LL-37 abrogates its direct
activity against HRV and that bronchial epithelial cells display
increased PAD enzyme expression and protein citrullination
upon HRV infection. This work describes functional changes
to the antiviral and immunomodulatory activities of LL-37 as a
consequence of a posttranslational modification that is relevant
in vivo and may reveal a novel mechanism that viral pathogens
employ to avoid the actions of HDP.
MATERIALS AND METHODS
Cell Culture and Reagents
Human bronchial epithelial cells (16HBE14
◦−) were obtained
from Professor Dieter Gruenert (UCSF). Cell culture vessels were
coated with 100µg/ml bovine serum albumin fraction V (Sigma
Aldrich, Dorset, UK), 0.5µg/ml Cultrex mouse collagen IV
(R&D Systems, Abingdon, UK), and 1µg/ml human fibronectin
(EMD Millipore, Hertfordshire, UK) before seeding. Cells
were grown in Iscove’s Modified Dulbecco’s Medium (IMDM),
GlutaMAXTM supplemented with 10% FBS (fetal bovine serum)
and 1%Penicillin-Streptomycin (Thermo-Fisher, Loughborough,
UK). WI-38 fetal lung fibroblasts and Hela cells were obtained
from ATCC. These cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% FBS and 1% Penicillin-
Streptomycin (Thermo-Fisher, Loughborough, UK). All cells
were grown in a heated humidified incubator at 37◦C, 5%
CO2. Cells were detached with 0.05% Trypsin-EDTA solution
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(Thermo-Fisher, UK) and seeded at 5 × 104 cells/ml for 12-
well plates and allowed to grow for 24 h before infection or
stimulation experiments. RNAzol-RT and Saponin were all
obtained from Sigma-Aldrich (Dorset, UK).
Antibodies
Antibodies against Citrullinated Histone H3 (ab5103), PAD2
(ab16478), PAD4 (ab128086), PAD3 (ab183209), Tubulin and β-
actin (ACTN05) were purchased from Abcam (Cambridge, UK).
The anti-peptidyl-citrulline antibody, clone F95 (MABN328)
was from EMD Millipore (Hertfordshire, UK). Antibodies
against total histone H3 (1B1B2) and (96C10) were from Cell
Signaling Technologies (Hertfordshire, UK). PAD1 (HPA062294)
was from Sigma Aldrich (Dorset, UK), and PAD2 (12110-1-
AP) was from Proteintech (Manchester, UK). All secondary
antibodies used were raised in goat. F(ab’)2 anti-Rabbit IgG
A647, F(ab’)2 anti-Mouse IgG PE (A10543), anti-Mouse IgG
A594 (A11032) and anti-Mouse IgG A488 (A11029) were from
Thermo Fisher Scientific (UK). Anti-Mouse IgM Texas Red was
from VectorLabs (Peterborough, UK) and Anti-Rabbit IgG FITC
was from Sigma Aldrich (Dorset, UK).
For flow cytometry, the following mouse anti human
antibodies CD3 PEcy7, CD16 PerCP-Cy 5.5, CD19 BV786, CD56
BV650, and CD14 PE were obtained from BD Biosciences
(Oxford, UK).
Isolation of Human PBMCs
Human venous blood was collected in accordance with local
institutional ethical and health & safety regulations. Peripheral
blood mononuclear cell (PBMC) and granulocyte cell fractions
were separated from the blood of healthy donors using
dextran sedimentation (Pharmacosmos, Reading, UK) followed
by discontinuous isotonic Percoll gradient centrifugation (GE
Healthcare, Amersham, UK). Granulocytes and PBMC were
washed twice in 1x DPBS without calcium or magnesium before
resuspension in RPMI 1640 (Thermo-Fisher, Loughborough,
UK). Purity was established by morphological assessment and
FACS analysis. PBMC were seeded in triplicate at 2 × 105 cells/
well in round bottom 96-well plates (Corning, Flintshire, UK)
and rested for 2 h in RPMI 1640 5% FBS before RV1B exposure
for 1 h in serum free RPMI media.
Peptides
Peptides were assembled using the Fmoc/tBu solid-
phase peptide synthesis approach (39) using either
model 433A (Applied Biosystems, CA, USA) or model
Liberty (CEM Corporation, NC, USA) automated peptide
synthesizers followed by cleavage in the trifluoroacetic
acid (TFA)/phenol/thioanisole/ethanedithiol/water (10:0.75:
0.5:0.25:0.5, w/w) mixture at 25◦C for 90min followed by
precipitation with cold diethyl ether. The crude peptides were
purified by preparative reversed-phase high-pressure liquid
chromatography (RP-HPLC). The peptide purity (>98%)
was confirmed by analytical RP-HPLC, and the masses were
confirmed by mass spectrometry. Following lyophilization,
the purified peptides were obtained in the form of their TFA
salts. Stock solutions (5 mg/mL) were prepared in ultrapure
DNAse/RNAse free water (Thermo-Fisher, Loughborough, UK)
and stored in aliquots at −80◦C. The sequences of the peptides
used in this study are shown in Table 1.
Virus Propagation and Infection
To generate viral stocks, HRV-16 and HRV-1B (Public Health
England Virus Collection, Salisbury, UK) were propagated in
Hela cells grown at 33◦C/5% CO2. Hela cells were tested and
shown to express high levels of ICAM-1 and LDLR by flow
cytometry. After 5 days, HRV infected cell or non-infected
cells (“Hela Lysate” control) were subjected to three freeze-thaw
cycles, harvested and spun to remove cellular debris (3,000 × g
for 30min) and frozen at−80◦C.
Virus stocks were concentrated and partially purified (40, 41).
Briefly, infected cell lysates were concentrated by centrifugation
with a 100,000-molecular weight cut-off Vivaspin-20 filter (2,000
rpm for 2 h at 4◦C; GE Healthcare, Amersham, UK). Soluble
factors from cell origin pass through the filter while the virus
is concentrated. Concentrated virus was then layered on a 30%
sucrose layer (30%, w/v, pH 7.2 in DPBS) and ultracentrifugated
in Quick-Seal R© Polypropylene 8mL tubes using a SW32.1Ti
swinging bucket rotor (Beckman Coulter) for 3 h at 25,000 rpm
at 16◦C. Cell pellets were washed, resuspended in DPBS and
aliquoted at−80
◦
C.
Virus titrations were performed in sub-confluent WI-38
cultures in 96-well plates using serial dilutions from the viral
stocks. Cells were infected for 2 h in serum free DMEM, washed
to remove inoculum and left for 6 days in DMEM 5% FBS at
33◦C/5% CO2 until CPE assessment was performed and TCID50
calculated using the Spearmen & Kärber algorithm and Reed
Muench method (47).
RNA Isolation, qPCR, and ELISA
Total RNA was extracted from 12-well plates using RNAzol RT.
RNA concentrations were determined using a NanoDrop 1000
spectrophotometer (Thermo Fisher Scientific, Loughborough,
UK). RNA integrity was checked using a 2100 Bioanalyzer
(Agilent, UK) with RIN values routinely >8. Total RNA (1
µg) was transcribed to cDNA with a Precision RT all-in-one
mix kit (PrimerDesign Ltd, Southampton, UK). cDNA (25 ng),
250 nM specific primers (Table 2) and SYBR green mastermix
(PrimerDesign Ltd, Southampton, UK) were used to perform
qPCR reactions in total volume of 20 µL in a StepOnePlus
instrument (Applied Biosystems). A panel of six human reference
genes were evaluated using a geNorm kit (PrimerDesign Ltd,
Southampton, UK) and qbase+ (Biogazelle, Belgium) software.
TABLE 1 | Sequences of native and citrullinated LL-37 peptides.
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
LL-371Cit LLGDFF(cit)KSKEKIGKEFKRIVQRIKDFLRNLVPRTES
LL-372Cit LLGDFF(cit)KSKEKIGKEFKRIVQRIKDFL(cit)NLVPRTES
LL-373Cit LLGDFF(cit)KSKEKIGKEFKRIVQRIKDFL(cit)NLVP(cit)TES
LL-375Cit LLGDFF(cit)KSKEKIGKEFK(cit)IVQ(cit)IKDFL(cit)NLVP(cit)TES
Scrambled LL-37 RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL
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TABLE 2 | qPCR Primer sequences utilized in this study.
Target Forward Reverse References
PADI1 TCTACTCGGACTGGC
TCTCTG
TGCTTCTTTTTGCCTG
GTGTTT
This work
PADI2 GCTTTCCTCTGTCTG
GTGGT
TTTCTTTGTGCCGGG
GATGG
This work
PADI3 CTGCAGAGAATCGTG
CGTGT
TGATCTCCAAAGTCG
CGTCAA
This work
PADI4 CCATCCTGCTGGTGA
ACTGT
GAAGTCCTTGGGGGT
CTTCG
This work
GAPDH AAGCTCATTTCCTGG
TATGACA
TCTTACTCCTTGGAG
GCCATGT
(42)
ACTB GGACTTCGAGCAAGA
GATGG
AGGAAGGAAGGCTG
GAAGAG
(43)
IL-6 GGTACATCCTCGACG
GCATCT
GTGCCTCTTTGCTGC
TTTCAC
(44)
CCL5 CAGTCGTCTTTGTCA
CCCGA
CGGGTGGGGTAGGA
TAGTGA
This work
IL-8 ACTGAGAGTGATTGA
GAGTGGAC
AACCCTCTGCACCCA
GTTTTC
(45)
Il-1β ACAGATGAAGTGCTC
CTTCCA
GTCGGAGATTCGTAG
CTGGAT
(46)
The geometric means of ACTB and GAPDH genes were selected
as the most stable combination for normalization in 16HBE14
◦−
cells. The 2−11Ct method was used and data is represented as
fold change over untreated cells.
To determine viral RNA copies in cells, total RNA was
extracted as indicated above, and a one-step RT-qPCR was
performed using 5 ng of total RNA as template together
with a Precision OneStepPLUS Master Mix (PrimerDesign Ltd,
Southampton, UK), and specific primers and FAM-taqman
probes included in theHumanRhinovirus kit (PrimerDesign Ltd,
Southampton, UK). RNA viral copies were extrapolated from the
Ct values generated using the standard curve.
ELISA measurements of IL-6, IL-8, and CCL-5 were
performed according to manufacturer’s instructions (R&D
Systems, Abingdon, UK).
Western Immunoblotting
Cells were lysed in ice-cold RIPA buffer (150mM NaCl, 1.0%
IGEPAL R© CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50mM
Tris, pH 8.0) from Sigma Aldrich (Dorset, UK), supplemented
with protease inhibitors (cOmpleteTM Mini, EDTA-free; Roche,
West Sussex, UK). Lysates were subjected to sonication (3
bursts of 10 s) and centrifuged at 12,000 x g for 15min at
4◦C. Proteins in the soluble fraction were quantified using
a Bradford Assay (Sigma Aldrich, Dorset, UK) and heated
(95
◦
C for 5min) in SDS-PAGE loading buffer. Equal amounts
of protein were separated by electrophoresis in 4–20% TGX
mini-protean gels (Biorad, Hertfordshire, UK). Samples were
transferred to PVDF membranes (Millipore) using a wet blotting
system and visualized with Ponceau S staining (Thermo Fisher,
Loughborough, UK). Membranes were blocked in 10% skimmed
milk powder (Marvell) in Tris Buffered Saline (TBS) 0.1%
Tween-20 (TBS-T) for 1 h at room temperature. The following
primary antibodies were diluted in 3%milk TBS-T and incubated
overnight at 4◦C; α-citrullinated histone H3 (1/2,500), α-PAD2
(1/1,000), α-PAD4 (1/2,000), α-total histone H3 (1/2,000), α-
β-actin (1/4,000). To detect protein citrullination, the F95
antibody was used at 1/1,000 with 5% BSA in TBS-T as blocking
solution. Membranes were incubated with α-Mouse IgG 800CW;
α-Mouse IgM 800CW or α-rabbit IgG 680IRdye secondary
antibodies (LI-COR Biosciences Odyssey R© Infrared Imaging
System, Cambridge, UK). Alternatively, horseradish peroxidase
(HRP)–conjugated antibodies (Agilent, Cheshire, UK) and ECL
Plus reagents (GE Healthcare, Amersham, UK) were used. Image
Studio Lite software (Licor) was used to quantify protein bands.
Confocal Microscopy
Cells were seeded on glass chambered cell culture slides (Corning,
Flintshire, UK) at 2 × 104 cells/well. After the indicated
exposures, cells were washed with DPBS and fixed with 4% PFA
for 20min at room temperature (RT). Cells were permeabilized
with 0.1% Triton X-100 and blocked with PBS 5% normal goat
serum (blocking buffer). Primary antibodies were diluted in
blocking buffer and incubated overnight at 4◦C. F95 and PAD2
antibodies were used at 1/100 dilution. After washing, goat anti-
rabbit or mouse IgM secondary antibodies diluted in blocking
buffer (1/1,000) were incubated with samples for 1 h at RT.
Final mounting was performed in Vectashield aqueous mounting
medium containing DAPI (Vector Laboratories, Peterborough,
UK), prior to visualization on a Zeiss LSM 880 AxioObserver Z1
confocal fluorescent microscope (wavelengths: 405, 488, 594 nm,
laser power 2%).
Flow Cytometry
16HBE14
◦− cells were seeded at a density of 1 × 105 cells/well
in 12-well plates in duplicate wells per experimental condition.
After treatment, cells were washed, detached with 0.05% Trypsin-
EDTA, placed in FACS tubes and fixed with 4% PFA at room
temperature for 15min. Cells were washed with PBS and
permeabilised by washing twice in PBS with 0.05% saponin. After
a blocking step in 5% goat serum, primary antibodies were left
overnight at 4
◦
C in PBS with 0.05% Saponin and 5% goat serum.
Fluorochrome conjugated secondary antibodies were added for
1 h at RT, and after final washing, cells were acquired in a FACS
Celesta instrument (BD Biosciences).
RESULTS
Citrullination of LL-37 Reduces the
Antiviral Activity of the Peptide Toward
Human Rhinovirus
Previous studies have shown that LL-37 is susceptible to
citrullination by PAD enzymes, with arginines 7, 29, and 34
in the sequence being preferentially targeted (30, 35). To
assess the impact of citrullination on the antiviral activity of
LL-37, we generated variants of LL-37 peptides with varying
numbers of arginine residues replaced with citrulline (Table 1).
We then tested the ability of the modified peptides to inhibit
HRV infection using the same prophylactic regime established
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previously (36). Briefly, RV1B virus was incubated with native
or modified LL-37 peptides and after 2 h incubation the
peptide/virus mixture was placed in contact with 16HBE14
◦−
bronchial epithelial cells for 1 h to allow infection. After washing,
cells were left for 24 h at 33◦C to allow viral replication. Cells
were harvested and HRV copy number quantified by qPCR. The
addition of native LL-37 reduced HRV copy number by∼80% at
both 10 and 30µg/ml (Figures 1A,B).
Substitution of one arginine residue to citrulline (LL-
371cit,) did not alter the antiviral effect at either concentration
tested. The substitution of two arginine residues (LL-372cit)
reduced LL-37 activity against HRV at 10µg/ml (Figure 1A).
However, this effect was not observed at the higher (30µg/ml)
concentration of LL-372cit (Figure 1B). Notably, LL-373cit lacked
all antiviral activity at 10µg/ml displaying a statistically
significant difference to native LL-37. However, at 30µg/ml, LL-
373cit, retained some activity against HRV. When all arginines in
LL-37 were substituted with citrulline (LL-375cit,) the antiviral
effect was significantly reduced when compared to native LL-
37 at 30µg/ml, and with an apparent, but non-statistically
significant loss of antiviral activity at 10µg/ml. We also
assessed a peptide with identical amino acid composition to
LL-37 but with a scrambled sequence (SCR) as a control
for exogenous peptide supplementation and to confirm that
effects of LL-37 were sequence specific (19). The addition of
LL-37-SCR at 30µg/ml did not cause a reduction in viral copy
number (Figure 1B).
To assess viral particle release from host cells, supernatants
collected from the same experiments were serially diluted and
used to infect WI-38 cells to measure viral titer by TCID50 assay.
In accord with the viral copy number assessment, virus titer in
cell supernatants decreased with LL-37 addition (Figure 1C) and
a gradual loss of this effect was observed when two or more
arginine residues were substituted with citrulline.
Citrullination of LL-37 Abrogates the
Antibacterial Activity of the Peptide Toward
S. aureus
To address whether the impact of citrullination on LL-37
function also extended to the antibacterial activity of the peptide
(30), 30 µg of native and modified peptides were incubated
in direct contact with Staphylococcus aureus (S. aureus) for
2 h, before enumeration on an agar plate after 24 h growth.
A 97% decrease in S. aureus CFU/ml was observed in the
presence of LL-37 (Figure 1D), an antibacterial effect that was
gradually reduced with each arginine to citrulline substitution,
with LL-372cit, LL-373cit, and LL-375cit all exhibiting statistically
FIGURE 1 | Citrullination of LL-37 abrogates the antiviral activity of the peptide toward human rhinovirus. Purified HRV1B viral particles were pre-treated with 10 µg
(A) or 30 µg (B) of native or differentially citrullinated LL-37 peptides (Table 1) for 2 h before incubation with 16HBE14
◦− cells for 1 h at a final MOI of 1. Cells were
washed to remove inoculum and incubated for 24 h before viral RNA in cells was addressed by qPCR. To measure released viral particles, cell supernatants from (B)
were serially diluted and exposed to WI-38 cells to obtain an infectious viral titer (TCID50/ml) (C). S. aureus bacteria was treated directly with 30µg/ml of the native
and modified LL-37 peptides for 2 h and incubated for 24 h before enumeration of colony formation units (CFU/ml) (D). Data represent mean values ± SEM for n = 3
experiments for each condition *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Statistical analysis performed by one-way ANOVA with Dunnet multiple comparisons test.
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significant differences to native LL-37 (p ≤ 0.05, p ≤ 0.01, and
p ≤ 0.001; respectively). Taken together, these data indicate that
citrullination of LL-37 profoundly affects its direct antiviral and
antibacterial activity.
Citrullination of LL-37 Alters the
Immunomodulatory Activities of the
Peptide
HRV infections are known to induce pro-inflammatory cytokine
and chemokine release from epithelial cells (2) and elevated
cytokines, in particular IL-8, correlate well with disease severity
(9). Thus, we examined the potential for native and citrullinated
forms of LL-37 to modulate HRV-induced pro-inflammatory
cytokine release. We assessed mRNA expression of IL-8
(Figure 2A), IL-6 (Figure 2B), and CCL5 (Figure 2C) by qPCR.
Infection with RV1B induced a marked increase in IL-8 (17-
fold over untreated), IL-6 (7-fold) and CCL5 (33-fold). Addition
of LL-37 reduced virus induced IL-8 mRNA expression by 81%
(∗p ≤ 0.05) and CCL5 by 84% (∗∗∗p ≤ 0.01) and also resulted
in a marked reduction of 71% in IL-6 mRNA levels (∗p ≤
0.05). In agreement with the effects of citrullinated LL-37 on
viral copy number, LL-371cit and LL-372cit caused a reduction
in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B.
Citrullination of three arginine residues in LL-373cit further
reduced the immunomodulatory activity of the peptide, whereas
LL-375cit completely lacked the ability to reduce IL-8, IL6, or
CCL5 mRNA, showing statistically significant differences when
compared to native LL-37. Addition of the LL37SCR control
peptide did not result in any measurable changes in cytokine
expression in response to HRV.
To assess changes at the protein level, we examined cell
supernatants by ELISA (Figures 2D–F). Notably, HRV infection
FIGURE 2 | Citrullination of LL-37 modulates cytokine expression and secretion induced by human rhinovirus. Purified HRV1B viral particles were pre-treated with 30
µg (A–C) or 10 µg (D–F) of native or differentially citrullinated LL-37 peptides for 2 h and incubated with 16HBE14
◦− cells for 1 h at a final MOI of 1. Cells were
washed to remove inoculum and left 24 h before RNA extraction. Levels of IL-8 (A), IL-6 (B), and CCL5 (C) mRNA transcripts were addressed by qPCR. Values
represent fold-changes over uninfected cells. Protein concentrations of IL-8 (D), IL-6 (E), and CCL5 (F) released into cell supernatants were assessed by ELISA. Data
represent mean values ± SEM for n = 3 experiments for each condition. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Statistical analysis performed by one-way ANOVA with
Dunnet multiple comparisons test.
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induced an increase in CCL5 secretion compared to untreated
cells, while the addition of LL-37 reduced this effect. The effects
of LL-371cit were indistinguishable from those of native LL-
37, whereas LL-372cit, and LL-373cit showed a moderate loss in
their ability to reduce HRV-induced CCL5 secretion. LL-375cit
exhibited no effect at any of the concentrations tested. However,
in contrast to gene expression, the data quantifying IL-6 and
IL-8 secretion was not statistically significant at this timepoint.
Taken together, this data suggests that LL-37 can modulate some
virus-induced proinflammatory cytokine gene expression and
protein release while total citrullination of the peptide abrogates
this function.
HRV Infection or Poly I:C Stimulation
Increases PAD2 Protein Levels in
16HBE14◦− Cells
Our results demonstrating that citrullination has a negative
impact on LL-37 function together with the increased presence of
PAD enzymes observed in lungs under inflammatory conditions
(29–31) led to the hypothesis that HRV infection may increase
levels of PAD enzymes and thus citrullination in epithelial
cells. We obtained RNA and protein from 16HBE14
◦− cells
post HRV infection and assessed PAD enzyme expression. In
our model, PADI2 mRNA was the most abundant isoform in
uninfected 16HBE14
◦− cells, being expressed at higher levels
than both PADI1 and PADI4. PADI3 mRNA levels were on
the limit of detection (data not shown). Given that LL-37 is
susceptible to PADI2 and PADI4 enzymatic activity (30), we
focused upon these two isoforms. Infection of 16HBE14
◦−
cells with HRV did not significantly alter mRNA levels of
either PADI2 (Figure 3A) or PADI4 (Figure 3D). In contrast,
protein levels of PAD2 (Figures 3B,C) and PAD4 (Figures 3E,F)
appeared to moderately increase after 24 and 48 h of HRV
infection, with comparable increases observed with the synthetic
dsRNA analog Poly I:C as measured by FACS. Importantly,
this effect was not observed when viral particles were UV-
irradiated, suggesting that in the context of HRV infection, active
replication of the virus is required for the increase in PAD
protein observed. We used Western immunoblotting to analyse
PAD2 protein levels in 16HBE14
◦− cells 24 h after infection and
a moderate increase in PAD2 was observed after 24 h of HRV
MOI 5 infection or treatment with Poly I:C (Figures 3G,H).
This was confirmed through the use of confocal microscopy to
analyse PAD2 protein levels in 16HBE14
◦− cells where a clear
increase in PAD2 staining was also observed after 48 h of HRV
MOI 5 infection, further confirming our observations by FACS
and Western immunoblotting (Figure 3I). PAD4 protein levels,
assessed byWestern immunoblotting, remained unchanged (data
not shown).
Interestingly, when Poly I:C was used as a synthetic analog of
a dsRNA viral infection, there was a statistically significant and
marked drop in PADI2 mRNA expression at 24 h and 48 h (p ≤
0.05 and p≤ 0.01, respectively; Figure 3A). A similar, statistically
significant drop was also observed for PADI4mRNA at 24 h (p≤
0.05, Figure 3D). However, protein levels of these two enzymes
were moderately increased both at 24 and 48 h time points in
response to Poly I:C administration at levels comparable to those
elicited by HRV infection (Figures 3C,F,G,H).
RV1B or Poly IC Stimulation Results in
Increased PAD2 Expression in PBMCs
Although epithelial cells are the main site of HRV replication,
immune cells are key contributors to the inflammatory response
to HRV. We aimed to assess whether HRV also increased PAD2
levels in PBMCs, primary cells with well-characterized levels
of PAD2 enzyme (48, 49). We obtained PBMCs from healthy
donors and exposed them to RV1B or poly I:C for 24 h or 48 h.
PAD2 expression was subsequently assessed in different immune
subsets by FACS analysis. We found that CD14+ CD16Low
monocytes (Figure 4C) expressed higher levels of PAD2 than
CD19+ B-cells (Figure 4B) or than CD3+ T-cells (Figure 4A).
Interestingly, HRV (MOI 5) infection or Poly I:C stimulation
resulted in a general increase in the levels of PAD2 across
the different PBMC subsets analyzed. T-cells, NK-T cells and
B-cells (Figures 4D-G) showed an increase in PAD2 levels at
24 h post-stimulation (data not shown), while in NK cells and
monocyte subsets the increase PAD2 was more pronounced
at 48 h (Figures 4F,H,I). In addition, increases in PAD2 were
abolished when UV-irradiated viral particles were used as control
(data not shown). A statistically significant increase in PAD2
expression was observed after 48 h RV1B MOI 5 infection, in
the CD14− CD16++ subset, confirming that HRV viral infection
is also able to increase PAD2 levels in non-epithelial cells.
These observations suggest that viral infection or binding of
ligand to Toll-Like Receptor-3 (TLR-3) can result in altered
PAD expression, which has the potential to impact on global
protein citrullination.
HRV Infection or Poly I:C Stimulation
Increase Protein Citrullination in Lung
Epithelium
To address whether the increased levels of PAD enzymes
observed after HRV infection resulted in increased protein
citrullination, we used a well-characterized monoclonal antibody
(F95) for the specific detection of citrullinated peptides (29, 50).
Using lysates from infected, poly I:C treated and untreated cells
for immunoblotting with the F95 antibody, we determined that
both HRV infection and poly I:C stimulation increased the
intensity of citrullinated proteins at 35–40 kDa. In addition,
a clear increase in a band ∼15 kDa was observed in the
presence of Poly I:C and HRV treatment (Figure 5A). Because
histones display a molecular weight ∼18 kDa and they are well-
characterized substrates for PAD enzymatic activity (51, 52), we
used an antibody to detect citrullinated histone H3 (Cit H3)
on the same lysates used in Figure 5A to confirm that Histone
H3 was being citrullinated. A clear increase in the citH3 band
intensity was observed in the presence of Poly I:C or HRV
stimulation (Figure 5B), confirming that citrullination of H3 is
increased under these stimuli.
We used confocal microscopy to assess total citrullinated
protein levels at different time points post HRV infection
(Figure 5C). After 24 and 48 h of infection, a clear increase in F95
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FIGURE 3 | Human rhinovirus and Poly I:C stimulation increase PAD2 protein expression in lung epithelial cells. Human bronchial epithelial (16HBE14
◦−) cells were
infected with HRV1B MOI = 5 for 6, 24 and 48 h before mRNA levels of PADI2 (A) and PADI4 (D) were assessed by qPCR. Poly I:C was used as positive control for
viral dsRNA. Protein levels of PAD2 (B) and PAD4 (E) at 24 or 48 h after RV1B infection were measured by FACS (PAD2 and PAD 4) and Western immunoblotting (PAD
2 only, 24 h post infection). UV irradiated virus (UV-RV1B) was used as replication deficient virus control. Values represent fold change expression over untreated cells
(dotted line) with data representing the mean ± SEM of 4 different experiments. Representative histogram plots for PAD2 (C) or PAD4 (F) protein expression in
16HBE14
◦− are shown. A representative Western immunoblot (representative of n = 3) together with quantification by densitometry are displayed (G,H), showing
enhanced PAD2 protein in 16HBE14
◦− cells after 24 h of RV1B infection at MOI = 5. Confocal microscopy images show enhanced PAD2 staining (red) in 16HBE14
◦−
cells after 48 h of RV1B infection at MOI = 1 or MOI = 5 (I). Statistical analysis in (A,D) was performed on 11CT values via a two-way ANOVA with Tukey multiple
comparisons test. $p ≤ 0.05, $$p ≤ 0.01 denoting significance on Poly I:C treatment vs. untreated (24 and 48 h, respectively). *p ≤ 0.05, **p ≤ 0.01.
staining and protein citrullination was detectable in the presence
of HRV (Figures 5C,D). Taken collectively these data suggest that
HRV infection, or activation of TLR3, results in increased protein
citrullination, including histone H3.
DISCUSSION
Previous studies have shown PAD2 and PAD4 isoforms
citrullinate LL-37 peptides in vitro, inhibiting the direct
antibacterial activity of LL-37 (30), the ability of LL-37
to enhance nucleic acid uptake and subsequent sensing by
plasmacytoid dendritic cells (53), and the ability of LL-37
to reduce inflammation in response to lipopolysaccharide
(LPS) (35). Our results confirm that citrullination abrogates
the antimicrobial and immunomodulatory activities of LL-
37 in the context of viral infection, and further show that
citrullination of LL-37 abrogates its antiviral activity, identifying
a novel role for citrullination in the innate response to
viral infection.
Airway epithelial cells are the main target of HRV infection
and replication. In response to infection, these cells can
release host defense peptides (11) which play a key role in
the inflammatory and innate immune responses (12). LL-
37 concentrations of ∼5µg/ml have been recovered in the
bronchoalveolar lavage fluid (BAL) from uninfected infants, with
levels up to ∼30µg/ml post infection (11, 54). Here we used
concentrations of exogenous LL-37 that mimic physiological
concentrations, and in agreement with our own recent studies
(36) and others (37, 38), show that direct incubation of LL-37
with HRV prior to infection of lung epithelial cells is effective
at reducing HRV RNA copy number and virion release into
cell supernatants.
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FIGURE 4 | Human rhinovirus and Poly I:C stimulation increase PAD2 expression in CD14−CD16++ PBMCs. Peripheral blood mononuclear cells (PBMC) were
isolated and exposed to different doses of HRV (viral MOI of 1 or 5) or to 10µg/ml of Poly I:C for 24 or 48 h. Intracellular PAD2 expression was assessed in different
PBMC subsets by FACS. Dot plots indicate the gating strategy used and histogram overlays indicate representative PAD2 levels (MFI) in different PBMCs subsets, (A)
CD3+ CD56− T-cells, (B) CD19+ CD3− CD56− B-cells, and (C) CD14+ CD16low CD19− CD3− CD56− Monocytes. Bars represent the Mean Fluorescence Index
(MFI) of PAD2 levels expressed in each PBMC subset after 48 h of infection: (D) T-cells, (E) NK-T cells, (F) NK-cells, (G) B-cells, (H) CD14− CD16++ monocytes, and
(I) CD14+ CD16low monocytes. Bars indicate the mean ± SEM of three different experiments. Statistical analysis was performed by a one way ANOVA with Tukey’s
multiple comparisons test (*p ≤ 0.05).
Inflammatory conditions that favor LL-37 release are known
to increase PAD enzyme levels and protein citrullination in
neutrophils (55), as well as in the lungs (29–31). PAD enzymes,
in particular PAD2, are released into extracellular spaces such
as cell-free BAL fluid (32) where they would encounter LL-37,
therefore LL-37 citrullination is likely to occur in extracellular
spaces under inflammatory conditions.
We assessed the impact of citrullination on the ability of
LL-37 to reduce HRV replication and found a striking loss of
antiviral activity when all arginines on LL-37 (LL-375cit) were
substituted with citrulline. Importantly, substituting only three
of the residues LL-373cit (Arg 7, 29 and 37) also drastically
reduced LL-37 antiviral activity. In contrast, substitution of only
1 residue (Arg 7) did not alter antiviral activity. While different
combinations of citrullinated residues in LL-37 peptide sequence
are possible, we used LL-37 peptides that are reported to be
generated after in vitro exposure to purified PAD2 or PAD4
enzymes, with mass spectrometry data indicating that arginine
residues 7, 29 and 34 are preferentially targeted by human PAD2
and PAD4 (30, 35). Each arginine conversion to citrulline reduces
Frontiers in Immunology | www.frontiersin.org 9 February 2020 | Volume 11 | Article 85
Casanova et al. LL-37 Citrullination and Rhinovirus
FIGURE 5 | Human rhinovirus and Poly I:C stimulation increase protein citrullination in 16HBE14
◦− cells. Human bronchial epithelial (16HBE14
◦−) cells were infected
with HRV1B MOI = 5 or treated with Poly IC and total citrullination was measured with a monoclonal antibody against peptidyl citrulline (F95). (A) After 24 h, lysates
were obtained and blotted with F95 antibody, α-citrullinated histone H3, and actin, which was used as loading control. (B) Confocal microscopy images were also
taken at 24 or 48 h after infection, showing F95 staining (RED) and DAPI as nuclear counterstaining (BLUE). (C) Quantification of at least four different fields of view
from (C) is shown in (D), with each dot representing a different cell and boxes displaying min to max and mean values of F95 staining intensity.
the net charge of LL-37 peptide, resulting in LL-375cit with
a +1 net charge, as opposed to the +6 net charge of native
LL-37 (30). This would affect the ability of LL-37 to interact
electrostatically with negatively charged molecules such as LPS
(56). Interestingly, while citrullination of LL-37 substantially
reduced the antibacterial activity of the peptide against S. aureus,
prior studies have determined that proteinases released by this
pathogen have the capacity to cleave LL-37, potentially at the
Arg19-Ile20 and Arg23-Ile24 bonds (57). Thus, it would be
interesting to determine the susceptibility of citrullinated forms
of the peptide in this context.
In line with this, LL-375cit is unable to reduce LPS-mediated
release of TNF-α due to a lack of LPS-binding capacity (35). Our
own data (36) suggests that the direct interaction of LL-37 with
viral particles is a key requirement to reduce HRV infection, as
treating viral particles with peptide prior to infection is the most
effective way to reduce HRV copy numbers. Similar results have
been observed with other viruses including RSV and influenza
(19, 58). We believe that citrullination alters the ability of LL-37
to interact with viral particles, in doing so disrupting the antiviral
activity of the peptide.
In addition to its direct antiviral activity, LL-37 has potent
and broad ranging immunomodulatory activity (59). Our
results show that incubation of HRV with LL-37 alters the
virus-mediated gene expression of IL-8, IL-6, and CCL5 mRNA
in response to infection. A reduction in viable HRV particles
may explain the lower gene expression levels of proinflammatory
cytokines observed, however, analysis of protein released into
the supernatant determined that incubation with LL-37 did
not directly correlate with significant changes at the protein
level. Interestingly, pre-incubation of RSV with LL-37 was
noted to limit the expression of IL-6, CCL5, and IP-10 in
response to infection (58). Recent studies have also demonstrated
that citrullination inhibits LL-37-mediated DNA uptake and
recognition by plasmacytoid dendritic cells (53). Given that LL-
37 has been shown to facilitate recognition of TLR3 ligands and
enhance responses to viral RNA (60), the implications of LL-
37 citrullination on enhancement of viral recognition should be
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a key area of focus. Our results indicate that citrullination of
LL-37 may alter inflammatory and innate immune responses
in infection, however further work is clearly required to
fully delineate whether this is skewed toward a pro- or anti-
inflammatory state in a clinical context.
We have shown for the first time that HRV infection increases
PAD2 protein expression in lung epithelial cells. The increase
in PAD2 protein expression is not observed when replication-
deficient (UV treated) HRV is used; suggesting that PAMPs
associated with viral replication may induce PAD expression.
One of these PAMPs would be dsRNA intermediates that signal
through TLR3. We show that a synthetic dsRNA and TLR3
agonist, poly I:C, is also capable of increasing PAD2 protein
levels. Interestingly, Poly I:C stimulation decreases expression
of PADI2 and PADI4 mRNA. This inconsistency between PAD
protein and mRNA levels has been reported previously (61).
An increase in PAD2 protein levels was also observed in PBMC
exposed to HRV or to Poly I:C, suggesting that increases in PAD
enzymes are part of immune cell activation (49, 62). This work
further characterizes PAD enzyme activity in PBMC, describing
for the first time, responses to a viral pathogen. The finding
that monocytes are a subset with highest PAD2 levels agrees
with the observation that monocytes demonstrate the strongest
citrullination responses within the isolated PBMC population
(63). In addition, we found statistically significant increases
in PAD2 in PBMCs with a phenotype compatible with “non-
classical” or “inflammatory” monocytes, a subset more prone
to the release of pro-inflammatory cytokines (64), strengthening
the notion that HRV-induced inflammation would increase PAD
and protein citrullination. Thus, by increasing PAD2-mediated
citrullination, HRV, and potentially other viruses, may be able
to citrullinate LL-37, reducing its efficacy and supporting viral
replication and persistence within host cells.
The total levels of citrullinated proteins in cells were also
found to be increased upon HRV infection. Immunostaining
patterns and multiple bands observed by immunoblotting
highlight multiple proteins being citrullinated. The presence
of citrullinated proteins in unstimulated cells suggests that
a basal rate of protein citrullination exists, however, this is
substantially increased upon HRV infection. To further confirm
these observations, we made use of citrullinated histone H3
(CitH3), a well-established readout of PAD activity (42, 43, 55).
We show that HRV infection or treatment of cells with poly I:C
results in increased CitH3 levels. Citrullination of histone H3
has also been used as an indicator of Neutrophil Extracellular
Trap (NET) release and may be of use as biomarker for certain
conditions such as sepsis (44). In this regard, adapted mouse
models of rhinovirus infection have shown the presence of NETS
after RV1B infection, suggesting that RV1B infection results in
H3 citrullination (45). Taken together, these findings suggest that
viral infection does result in increased protein citrullination, both
in human bronchial epithelial cell lines and in mouse models of
HRV infection.
HRV infection and replication in epithelial cells results in
the secretion of a variety of cytokines and chemokines which
recruit immune cells to the lungs leading to neutrophil activation.
It has been established that increased PAD2 protein expression
and citrullinated proteins are observed in the lungs under
certain inflammatory conditions, such as in response to smoking
(29, 31), nanoparticles or pollutants (33) or in COPD, with
PAD2 histological staining showing strong reactivity in bronchial
epithelial cells and in infiltrated leukocytes (30). Our data now
suggests that HRV infections would also result in increases in
PAD and citrullinated protein levels in the lungs.
We propose that abnormally elevated PAD activity would
result in LL-37 citrullination, thus rendering the peptide
ineffective against HRV or other respiratory pathogens.
Furthermore, given the immunomodulatory effects of LL-37,
citrullination of the peptide could also lead to exaggerated
pro-inflammatory responses (35). Together, this may contribute
to secondary bacterial infections and exacerbations of pre-
existing conditions observed in susceptible individuals, which
are important factors in HRV epidemiology (2). In instances of
viral infection, the degree to which LL-37 is citrullinated, and
the specific amino acid residues that are preferentially targeted
will likely reflect which PAD enzymes are induced as a result of
the infection. A full assessment of PAD expression in clinical
instances of viral infection may have utility for predicting altered
innate responses. Therefore, we suggest that further work is
required to develop better tools to characterize citrullination,
particularly HDP citrullination, and to establish prevalence in
other viral infections.
We anticipate the findings of this work will also apply to
other host defense molecules where cationicity and arginine
residues are important for antimicrobial function. In this
regard, post-translational modifications affecting arginine
have been described in human defensin-1 (HNP-1) (46)
affecting its antibacterial activity. We and others have shown
that cathelicidins show promise as antivirals against HRV,
influenza, RSV and other respiratory pathogens (19, 20, 36).
However, host mediated modifications of this peptide, such
as citrullination, may limit its effectiveness. Significantly,
another posttranslational modification affecting the cationicy
of LL-37 has also been reported. Carbamylation results in
the non-enzymatic conversion of lysine residues to neutral
homocitrulline (65, 66) and thus reduces the net positive
charge of LL-37. Similarly to citrullinated LL-37, carbamylated
LL-37 also displays reduced direct antibacterial activity and
reduced ability to modulate LPS-mediated cytokine release (65),
confirming the importance of positive charge in the normal
function of LL-37.
In summary, our data suggests that strategies oriented
toward engineering citrullination resistant host defense
peptides or reducing abnormally elevated levels of PAD
enzyme activity may reduce the severity of HRV and other
viral pathogens, and in turn reduce the risk of secondary
bacterial infections and exacerbations of pre-existing
pulmonary conditions.
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